The FDA granted two priority reviews: one for a potential Pfizer vaccine for kids and the other for Roche’s bispecific antibody glofitamab, the companies announced Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,